



7<sup>th</sup> IMAD meeting

INSTITUTE  
of HUMAN  
GENETICS

POLISH  
ACADEMY  
of SCIENCES



# Polymorphisms of genes encoding selenoproteins influence the growth of abdominal aortic aneurysm (AAA) – a study in Polish population

Ewa Strauss<sup>1, 2, 4</sup>, Łukasz Kruszyna,<sup>2</sup>; Jolanta Tomczak,<sup>2</sup>; Marta Stelcer<sup>3</sup>; Zbigniew Krasiński,<sup>2</sup>; Grzegorz Oszkinis<sup>3,4</sup>

1 Institute of Human Genetics, Polish Academy of Sciences,

2 Department of Vascular and Endovascular Surgery, Angiology and Phlebology, Poznan University of Medical Sciences,

3 Department of General and Vascular Surgery, Poznan University of Medical Sciences,

4 Department of Vascular and General Surgery, University Hospital, Opole University, Medical College, Opole, Poland


# AIM

---

This study examines the associations of **functional SNPs** in **11 candidate genes for cardiovascular disease (CVD)**, including those involved in determining

- blood pressure,
  - lipid profile,
  - homocysteine levels,
  - response to hypoxia and oxidative stress
- with the **growth rate of AAA**.

# METHODS



## Inclusion criteria:

- AAA  $\geq 30$  mm
- $\geq 2$  control examination of aneurysm diameter during 1 year
- both sexes

## TaqMan-genotyping of 11 SNPs in genes:


*AGTR1, ApoE, GPX4, HIF1A, MTHFR, PON1, SELENOS, SEPP1, SOD2, TXNRD1, TXNRD2,*

## Statistical analysis:

- the development of AAA progression models using GLM methods
- **growth rates estimated for growth within the specified AAA size ranges, in 10 mm increments ( $\pm 2$  mm) covering AAA growth from 30 - 70 mm**
- analysis of association

# METHODS

## Flow chart describing selection of study patients



## The characteristics of study group

Parameter	AAA N=288
Age [years]	68.3 $\pm$ 7.1
Men	82.3%
Cigarette smoking, current	34.6%
Arterial hypertension	83.6%
Diabetes	28.7%
Hyperlipidemia	85.0%
AAA $\geq$ 50 mm	42.8%
AAA growth rate [mm/y]	3.7 $\pm$ 4.7
No. of ultrasound scans	6.1 $\pm$ 2.9
Follow-up, years	3.9 $\pm$ 2.2
Elective AAA repair	34.0%

# RESULTS







FIGURE AAA growth rates estimated for specified size ranges (n=442 individual observations)



## FACTORS ASSOCIATED WITH ANNUAL AAA GROWTH RATE




## FACTORS ASSOCIATED WITH ANNUAL AAA GROWTH RATE



- Patients with larger AAAs >39 mm had decreased blood SeP [ng/ml] concentration (insufficient antioxidant barrier)

## FACTORS ASSOCIATED WITH ANNUAL AAA GROWTH RATE







Present **SMOKING**, the main modifier of **Se status in the body**, was the only CVD risk factor associated with faster AAA growth.






# CORRELATION OF SELENOPROTEIN P (SeP) LEVELS WITH LIPID PROFILES IN THE POPULATION OF 105 PATIENTS WITH AAA AND 75 CONTROL SUBJECTS



*In AAA SeP concentration was*

- positively correlated with HDLC*
- negatively correlated with TG*

# SELENOPROTEINS



- 25 proteins that include selenium
- act against oxidative stress




Antioxidant enzymes	Redox signaling	Thyroid hormone metabolism	Sec synthesis	Se transport and storage	Protein folding	Unknown function
GPX1	TXNRD1	DOI1	SPS2	<b>SEPP1</b>	Sep15	SelH
GPX2	TXNRD2	DOI2			SEPN1	SelI
GPX3	TXNRD3	DOI3			SelM	SelO
<b>GPX4</b>					<b>SelS</b>	SelT
GPX6						SelV
SelK						
SepX1						
SepW						
<b>SOD2</b>						

**SEPP1** : Ex5 –rarer allele favors the production of a low Se isoform of protein)

**GPX4- 3'-UTR** -alters the protein binding to the 3'-UTR and reporter gene activity,


**SNPs associated with AAA growth influenced the effects of Se supplementation in clinical trials**



## SeP AND SELENOPROTEIN SNPS vs CVD

Protein/Gene	Parameter/SNP	Effect
<b>SeP</b>	Levels increased	<ul style="list-style-type: none"> <li>presence of diabetes</li> <li>glucose intolerance</li> <li>thickening of the intima-media complex in the carotid artery</li> </ul>
	Levels decreased	<ul style="list-style-type: none"> <li>gestational diabetes mellitus</li> </ul>
	Expression increased	<ul style="list-style-type: none"> <li>in macrophages with anti-atherosclerotic function (implies a protective role of SeP in CVD)</li> <li>act as an antiangiogenic factor, retarding perfusion recovery in response to ischemia in diabetic peripheral and coronary atherosclerosis</li> </ul>
<b>SEPP1</b>	<i>rs7579A</i>	<ul style="list-style-type: none"> <li>SNPs affect the bioavailability of Se</li> <li>abdominal aortic aneurysm</li> </ul>
	<i>rs3877899</i>	<ul style="list-style-type: none"> <li>SNPs affect the bioavailability of Se</li> <li>abdominal aortic aneurysm</li> </ul>

Protein/Gene	Parameter/SNP	Effect
<b>GPX4</b>	<i>rs713041</i>	<ul style="list-style-type: none"> <li>concentrations of inflammatory biomarkers</li> <li>cerebral stroke</li> <li>endothelial dysfunction</li> </ul>
	<i>rs4807542</i>	<ul style="list-style-type: none"> <li>concentrations of inflammatory biomarkers</li> </ul>
<b>SELENOS</b>	<i>rs4965814</i>	<ul style="list-style-type: none"> <li>ischemic stroke</li> </ul>
	<i>rs28628459</i>	<ul style="list-style-type: none"> <li>self-reported history of prior CVD</li> <li>carotid atherosclerosis</li> <li>self-reported history of prior CVD</li> </ul>
	<i>rs7178239</i>	<ul style="list-style-type: none"> <li>carotid atherosclerosis</li> <li>ischemic stroke</li> </ul>
	<i>rs8025174</i>	<ul style="list-style-type: none"> <li>carotid atherosclerosis</li> <li>coronary artery disease</li> </ul>
	<i>rs9806366</i>	<ul style="list-style-type: none"> <li>self-reported history of prior CVD</li> </ul>
	<i>rs28665122</i>	<ul style="list-style-type: none"> <li>carotid atherosclerosis</li> </ul>
	<i>rs12917258</i>	<ul style="list-style-type: none"> <li>coronary atherosclerosis</li> </ul>



- Primarily studied in malignant diseases,
- Growing evidence on their role in CVD

(Strauss et al: Scient Rep 2014; PloS One 2018).

# SELENIUM & AAAs

## 1. Decreased blood Se levels in AAA

Vasa 2011; 40: 381–389  
© 2011 by Hans Huber Publishers, Hogrefe AG, Bern

Original communication

### Diet and the content of selenium and lead in patients with abdominal aortic aneurysm

K. Socha<sup>1</sup>, M. H. Borawska<sup>1</sup>, M. Gacko<sup>2</sup> and A. Guzowski<sup>2</sup>

<sup>1</sup>Medical University of Białystok, Department of Bromatology, Białystok, Poland

<sup>2</sup>Medical University of Białystok, Department of Vascular Surgery and Transplantation, Białystok, Poland

No	Selenium	n	Control group mean ± SD (min. – max.)	n	Patients with AAA mean ± SD (min. – max.)	p value
1	Serum (µg/L)	22	75.87 ± 22.4 (46.57 – 149.42)	49	60.37 ± 21.2 (17.65 – 113.34)	0.0075*
2	Aortic wall (ng/g)	17	55.44 ± 34.4 (14.07 – 124.70)	40	52.31 ± 47.1 (10.05 – 219.13)	0.839
3	Parietal thrombus (ng/g)	–	–	37	139.82 ± 44.6 (51.91 – 257.21)	–

## 3. Correlations between serum TRX with AAA size and expansion rate





Fig. 2. TRX levels in AAA. (A) TRX levels are significantly increased in serum of patients with AAA (n = 30) vs. controls (n = 15) (\*p < 0.05). (B) TRX levels are significantly increased in serum of patients with large AAA (n = 24) in relation to small AAA (n = 34) and controls (n = 15) (\*p < 0.05).



**Conclusions:** TRX release is increased in the luminal part of AAA and TRX serum levels are increased in AAA patients compared with healthy subjects. TRX levels correlates with AAA size and expansion, suggesting its potential role as a biomarker of AAA evolution.



Redox Report  
Communications  
in Free Radical Research

## 2. Decrease of plasma levels of Se as AAA size increased

Table 2 Mean plasma levels of oxidative stress biomarkers in control subjects and AAA patients

Variable	Control group (n = 18)	AAA ≤50 mm (n = 15)	AAA >50 mm (n = 12)	P-value**
Vitamin C (µg/ml)	10.9 ± 3.85	9.15 ± 2.73	7.35 ± 3.16	0.011
α-Tocopherol (µg/ml)	14.5 ± 3.34	12.4 ± 3.14	11.6 ± 2.91	0.016
γ-Tocopherol (µg/ml)	0.81 ± 0.38	0.92 ± 0.49	0.66 ± 0.29	0.50
Cholesterol (g/l)	2.04 ± 0.35	1.79 ± 0.54	1.62 ± 0.46	0.020
α-Tocopherol /chol (mg/g)	7.16 ± 1.44	7.10 ± 1.31	7.38 ± 1.64	0.71
β-Carotene (mg/l)	0.29 ± 0.17	0.20 ± 0.18	0.11 ± 0.054	0.0096
Thiol proteins (µM)	311 ± 38	337 ± 45.7	312 ± 41.0	0.48
Ubiquinone (mg/l)	0.84 ± 0.32	0.70 ± 0.23	0.57 ± 0.21	0.014
Copper (mg/l)	0.88 ± 0.12	0.90 ± 0.26	0.90 ± 0.32	0.79
Zinc (mg/l)	0.79 ± 0.14	0.73 ± 0.10	0.63 ± 0.13	0.0035
Copper/zinc ratio	1.14 ± 0.21	1.24 ± 0.38	1.43 ± 0.42	0.046
Selenium (µg/l)	92.7 ± 16.4	83.8 ± 18.3	70.4 ± 21.0	0.0038
Lipid peroxides (µM)*	520 ± 228	574 ± 360	563 ± 307	0.82
Oxidized LDL (ng/ml)*	756 ± 964	205 ± 244	264 ± 220	0.062
Antibodies against oxidized LDL	263 ± 282	255 ± 308	148 ± 87.5	0.32
Isoprostanes (ng/ml)	1.01 ± 0.66	1.19 ± 0.64	1.68 ± 0.89	0.052
Paraoxonase (ng/ml)*	105 ± 61.1	127 ± 89.0	136 ± 72.2	0.26
Total glutathione (µM)*	852 ± 203	960 ± 148	922 ± 209	0.20
Oxidized glutathione (µM)*	1.01 ± 0.67	4.58 ± 11.0	4.93 ± 13.3	0.33
Glutathione peroxidase (UI/g Hb)	51.5 ± 9.97	51.5 ± 11.5	51.0 ± 10.6	0.91
Myeloperoxidase (ng/ml)*	22.0 ± 24.4	53.4 ± 76.6	48.8 ± 95.9	0.28



## Conclusions

- **The observed associations confirm the role of selenoproteins and oxidative stress in the progression of AAA.**
- The role of SNPs *SELENOP* rs3877899 and *GPX4* rs713041 in AAA progression is a novel observation

